All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the MPN Hub steering committee roundtable discussion we were pleased to invite Dr Haifa Kathrin Al-Ali University Hospital Halle (Saale), Halle, Germany to give a presentation on how to treat cytopenic patients with MPN.
How to treat cytopenic patients with MPN
Dr Al-Ali opens the presentation by outlining the differences between cytopenic and myeloproliferative MF before giving an overview of the various treatment options available to cytopenic patients and their role in the clinical landscape. She concludes by highlighting investigational agents currently in clinical trials.
ASH 2022 abstracts: What’s hot in MPN?
To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee members provided their recommendations for the top...
Dysregulation of the bone marrow niche contributes to the pathogenesis of myeloproliferative neoplasms
The bone marrow niche is the local tissue microenvironment that maintains and regulates stem cells for hematopoiesis. It is comprised of many...
Subscribe to get the best content related to MPN delivered to your inbox